Dr. Laheru is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
401 N. Broadway
Baltimore, MD 21231Phone+1 410-955-8964- Is this information wrong?
Summary
- Dr. Daniel Laheru is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 22 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gastrointestinal oncology, general medical oncology, and pancreatic cancer, immunotherapy.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Utah HealthResidency, Internal Medicine, 1995 - 1998
Baylor College of MedicineClass of 1995
Certifications & Licensure
VA State Medical License 2024 - 2026
MD State Medical License 1998 - 2024
PA State Medical License 2020 - 2022
NC State Medical License 2020 - 2022
UT State Medical License 1996 - 2004- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2010-2013
- Join now to see all
Clinical Trials
- Individualized Drug Treatment for Treating Patients With Pancreatic Cancer Start of enrollment: 2005 Oct 01
- Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer Start of enrollment: 2005 Dec 01
- Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer Start of enrollment: 2006 Sep 11
- Join now to see all
Publications & Presentations
PubMed
- Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.Seyda Baydogan, Parul Agarwal, Robin D Wright, Laura R Prakash, Maureen E Mork, Alison P Klein, Jessica E Maxwell, Matthew H G Katz, Arvind Dasari, Michael P Kim, Jin ...> ;Cancer Prevention Research. 2024 Apr 25
- 1 citationsNeoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.Wang, J., Gai, J., Zhang, T., Niu, N., Qi, H., Thomas, D., Li, K., Xia, T., Rodriguez, C., Parkinson, R., Durham, J., McPhaul, T., Narang, A., Anders, R., Osipov, A., ...> ;Science Advances. 2024 Feb 9
- Association of Long-Term, New-Onset, and Postsurgical Diabetes With Survival in Patients With Resectable Pancreatic Cancer: A Retrospective Cohort Study.Sarah Kanbour, Gayane Yenokyan, Mohammed Abusamaan, Daniel Laheru, Ayman Alam, Marie Line El Asmar, Zunaira Virk, Dylan Hardenbergh, Nestoras Mathioudakis> ;Pancreas. 2023 Jul 1
- Join now to see all
Journal Articles
- Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant ChemotherapyAlex B Blair, Joseph Herman, Martin Makary, John L Cameron, Amol Narang, Daniel Laheru, Christopher Wolfgang, Matthew J Weiss, Ammar A Javed, Jin He, Journal of gastrointestinal surgery
Press Mentions
Overcoming Challenges to Vaccine ImmunotherapyNovember 29th, 2017
Facing End-of-Life Talks, Doctors Choose to WaitJanuary 11th, 2010
Hospital Affiliations
Johns Hopkins HospitalBaltimore, Maryland
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/daniel-laheru
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
